Eikon Therapeutics Common Stock Overview

Eikon Therapeutics Common Stock Research & Development

Research & Development expenses for EIKN.

Quarterly R&D Expenses

$70.05M

As of Mar 31, 2026

Annual R&D Expenses (TTM)

N/A

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin